<DOC>
	<DOCNO>NCT00993109</DOCNO>
	<brief_summary>This multi-center , prospective , randomize , open-label , parallel design , two arm comparator trial . In proposed study , investigator compare low-dose combination therapy Nifedipine GITS/OROS plus Valsartan up-titrated monotherapy Valsartan respect blood pressure-decreasing effect patient essential hypertension.The study consist screen visit , follow randomization administration either Nifedipine GITS/OROS 30 mg combination Valsartan 80 mg Valsartan 160 mg 12 week treatment.The primary efficacy parameter mean SBP DBP office BP monitoring 12 week treatment compare baseline .</brief_summary>
	<brief_title>Low-dose Nifedipine-Valsartan Combination Compared Up-titrated Valsartan Monotherapy Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Men woman age 18 75 year Essential hypertension well control current low dose ( 80 mg ) valsartan monotherapy least 4 week . Patients prior treatment monotherapy diuretic , ACEI beta blocker ARB valsartan switch current low dose valsartan 80 mg monotherapy least 4 week also eligible , provide hypertension still well control . Office systolic blood pressure ( sit ) &gt; 140 mmHg ( sit &gt; /= 5 min. , cigarettes and/or coffee/tea &gt; /=30 min . BP measurement ) . BMI &lt; 33 kg/m2 Participation clinical investigational drug study within previous 12 week Concomitant treatment : 1 . Any antihypertensive treatment Valsartan 80 mg 2 . Cytochrome P4503A4 inhibitor inducer 3 . Potassiumsparing diuretic Severe hypertension ( DBP &gt; /= 110 mm Hg and/or SBP &gt; /= 180 mm Hg ) and/or evidence secondary form hypertension Any following cardiovascular disease : History cardiovascular shock Myocardial infarction unstable angina within previous 6 month Severe cardiac valve disease Past present severe rhythm conduction disorder . Cerebrovascular ischemic event and/or history intracerebral hemorrhage subarachnoid hemorrhage ( SAH ) within previous 12 month Type 1 2 diabetes mellitus Proteinuria Uncorrected hypokalemia hyperkalemia , sodium depletion and/or hypovolemia Gastrointestinal disease result potential malabsorption and/or severe gastrointestinal tract narrowing ; kock pouch ( ileostomy proctocolectomy ) Cholestasis biliary obstruction Liver disease aspartate aminotransferase ( AST ) / alanine aminotransferase ( ALT ) level &gt; 3 x upper limit normal ( ULN ) Renal failure , creatinine level &gt; 2.0 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Nifedipine GITS/OROS ( Adalat® )</keyword>
	<keyword>Valsartan ( Diovan® )</keyword>
	<keyword>Hypertension</keyword>
</DOC>